Samuel A Acquah
Examiner (ID: 1213)
Most Active Art Unit | 1711 |
Art Unit(s) | 2899, 1207, 1711, 1503, 1774, 1754 |
Total Applications | 2690 |
Issued Applications | 2329 |
Pending Applications | 91 |
Abandoned Applications | 269 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 9670451
[patent_doc_number] => 20140234314
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-21
[patent_title] => 'ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/266387
[patent_app_country] => US
[patent_app_date] => 2014-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 60
[patent_figures_cnt] => 60
[patent_no_of_words] => 35724
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14266387
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/266387 | ANTIBODIES AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND USES THEREOF | Apr 29, 2014 | Abandoned |
Array
(
[id] => 9798611
[patent_doc_number] => 20150010555
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-01-08
[patent_title] => 'COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE'
[patent_app_type] => utility
[patent_app_number] => 14/261212
[patent_app_country] => US
[patent_app_date] => 2014-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 20389
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14261212
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/261212 | COMPOSITIONS AND METHODS FOR INCREASING SERUM HALF-LIFE | Apr 23, 2014 | Abandoned |
Array
(
[id] => 16354401
[patent_doc_number] => 10794907
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
[patent_app_type] => utility
[patent_app_number] => 14/258617
[patent_app_country] => US
[patent_app_date] => 2014-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 41
[patent_no_of_words] => 27340
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14258617
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/258617 | Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent | Apr 21, 2014 | Issued |
Array
(
[id] => 10729606
[patent_doc_number] => 20160075755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-03-17
[patent_title] => 'IMMUNOSUPPRESSIVE TGF-ß SIGNAL CONVERTER'
[patent_app_type] => utility
[patent_app_number] => 14/785248
[patent_app_country] => US
[patent_app_date] => 2014-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 16549
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14785248
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/785248 | Immunosuppressive TGF-b signal converter | Apr 16, 2014 | Issued |
Array
(
[id] => 9635368
[patent_doc_number] => 20140213478
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-07-31
[patent_title] => 'SRM/MRM Assay for the Receptor Tyrosine-Protein Kinase erbB-4 Protein (HER4)'
[patent_app_type] => utility
[patent_app_number] => 14/245769
[patent_app_country] => US
[patent_app_date] => 2014-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6711
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14245769
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/245769 | SRM/MRM assay for the receptor tyrosine-protein kinase erbB-4 protein (HER4) | Apr 3, 2014 | Issued |
Array
(
[id] => 9698943
[patent_doc_number] => 20140248628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-04
[patent_title] => 'ISOFORMS OF THE HUMAN SST5 RECEPTOR ORIGINATED BY ALTERNATIVE SPLICING AND OLIGONUCLEOTIDE PAIRS TO DETECT THEM BY PCR'
[patent_app_type] => utility
[patent_app_number] => 14/243734
[patent_app_country] => US
[patent_app_date] => 2014-04-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 4811
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14243734
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/243734 | ISOFORMS OF THE HUMAN SST5 RECEPTOR ORIGINATED BY ALTERNATIVE SPLICING AND OLIGONUCLEOTIDE PAIRS TO DETECT THEM BY PCR | Apr 1, 2014 | Abandoned |
Array
(
[id] => 11698836
[patent_doc_number] => 09688739
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-06-27
[patent_title] => 'T cell receptors and related materials and methods of use'
[patent_app_type] => utility
[patent_app_number] => 14/221823
[patent_app_country] => US
[patent_app_date] => 2014-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 21694
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14221823
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/221823 | T cell receptors and related materials and methods of use | Mar 20, 2014 | Issued |
Array
(
[id] => 11612593
[patent_doc_number] => 09650442
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-05-16
[patent_title] => 'Bispecific anti-EGFR/anti IGF-1R antibodies'
[patent_app_type] => utility
[patent_app_number] => 14/220952
[patent_app_country] => US
[patent_app_date] => 2014-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 26123
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 223
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14220952
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/220952 | Bispecific anti-EGFR/anti IGF-1R antibodies | Mar 19, 2014 | Issued |
Array
(
[id] => 10700574
[patent_doc_number] => 20160046721
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-02-18
[patent_title] => 'ANTIBODIES AND METHODS FOR TREATING ESTROGEN RECEPTOR-ASSOCIATED DISEASES'
[patent_app_type] => utility
[patent_app_number] => 14/778686
[patent_app_country] => US
[patent_app_date] => 2014-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 30
[patent_no_of_words] => 30053
[patent_no_of_claims] => 65
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14778686
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/778686 | Antibodies and methods for treating estrogen receptor-associated diseases | Mar 18, 2014 | Issued |
Array
(
[id] => 10687386
[patent_doc_number] => 20160033531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2016-02-04
[patent_title] => 'METHOD AND COMPOSITIONS FOR DETECTING BINDING TO THE PREGNANE X RECEPTOR'
[patent_app_type] => utility
[patent_app_number] => 14/773901
[patent_app_country] => US
[patent_app_date] => 2014-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 17511
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14773901
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/773901 | METHOD AND COMPOSITIONS FOR DETECTING BINDING TO THE PREGNANE X RECEPTOR | Mar 14, 2014 | Abandoned |
Array
(
[id] => 9756267
[patent_doc_number] => 20140286969
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-25
[patent_title] => 'ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS'
[patent_app_type] => utility
[patent_app_number] => 14/211954
[patent_app_country] => US
[patent_app_date] => 2014-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 36775
[patent_no_of_claims] => 39
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14211954
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/211954 | ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS | Mar 13, 2014 | Abandoned |
Array
(
[id] => 12086840
[patent_doc_number] => 09840560
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-12-12
[patent_title] => 'Monoclonal antibodies to EGFR, and uses therefor'
[patent_app_type] => utility
[patent_app_number] => 14/209976
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 26
[patent_figures_cnt] => 37
[patent_no_of_words] => 23411
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14209976
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/209976 | Monoclonal antibodies to EGFR, and uses therefor | Mar 12, 2014 | Issued |
Array
(
[id] => 13038001
[patent_doc_number] => 10041125
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-08-07
[patent_title] => Assay for predictive biomarkers
[patent_app_type] => utility
[patent_app_number] => 14/207879
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2642
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 164
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14207879
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/207879 | Assay for predictive biomarkers | Mar 12, 2014 | Issued |
Array
(
[id] => 9739186
[patent_doc_number] => 20140274905
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'METHODS AND COMPOUNDS FOR CALCIUM ION CHANNEL REGULATION'
[patent_app_type] => utility
[patent_app_number] => 14/209345
[patent_app_country] => US
[patent_app_date] => 2014-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 7034
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14209345
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/209345 | METHODS AND COMPOUNDS FOR CALCIUM ION CHANNEL REGULATION | Mar 12, 2014 | Abandoned |
Array
(
[id] => 10905188
[patent_doc_number] => 20140308201
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-16
[patent_title] => 'ANTIBODY DRUG CONJUGATES'
[patent_app_type] => utility
[patent_app_number] => 14/204023
[patent_app_country] => US
[patent_app_date] => 2014-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 54570
[patent_no_of_claims] => 49
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14204023
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/204023 | Antibody drug conjugates | Mar 10, 2014 | Issued |
Array
(
[id] => 9735963
[patent_doc_number] => 20140271675
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'THERAPEUTIC USES FOR VEGFR1 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 14/203675
[patent_app_country] => US
[patent_app_date] => 2014-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16270
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14203675
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/203675 | Therapeutic uses for VEGFR1 antibodies | Mar 10, 2014 | Issued |
Array
(
[id] => 11282695
[patent_doc_number] => 09498532
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-11-22
[patent_title] => 'Antibody drug conjugates'
[patent_app_type] => utility
[patent_app_number] => 14/203997
[patent_app_country] => US
[patent_app_date] => 2014-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 38
[patent_figures_cnt] => 20
[patent_no_of_words] => 54590
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 91
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14203997
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/203997 | Antibody drug conjugates | Mar 10, 2014 | Issued |
Array
(
[id] => 10919194
[patent_doc_number] => 20140322212
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-30
[patent_title] => 'EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS'
[patent_app_type] => utility
[patent_app_number] => 14/184895
[patent_app_country] => US
[patent_app_date] => 2014-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 49
[patent_figures_cnt] => 49
[patent_no_of_words] => 54525
[patent_no_of_claims] => 68
[patent_no_of_ind_claims] => 19
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14184895
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/184895 | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells | Feb 19, 2014 | Issued |
Array
(
[id] => 10919256
[patent_doc_number] => 20140322275
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-10-30
[patent_title] => 'TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR'
[patent_app_type] => utility
[patent_app_number] => 14/184924
[patent_app_country] => US
[patent_app_date] => 2014-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 56356
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14184924
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/184924 | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor | Feb 19, 2014 | Issued |
Array
(
[id] => 9671099
[patent_doc_number] => 20140234962
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-21
[patent_title] => 'Ligands Modified by Circular Permutation as Agonists and Antagonists'
[patent_app_type] => utility
[patent_app_number] => 14/182536
[patent_app_country] => US
[patent_app_date] => 2014-02-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 19247
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14182536
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/182536 | Ligands modified by circular permutation as agonists and antagonists | Feb 17, 2014 | Issued |